LAVAL, QC, Feb. 21 /PRNewswire-FirstCall/ - In light of Neurochem Inc.'s (NASDAQ: NRMX; TSX: NRM) new strategic direction, the Company announces the departure, effective February 21, 2008, of two members of its senior management team, Dr. Andreas Orfanos, MBB. Ch, MBA, Executive Vice President, Strategic Planning and Scientific Affairs, and Ms. Christine Lennon, MBA, Vice President, Business Development. The possibility of their acting as consultants in respect of specific projects is being explored.
"On behalf of the Board of Directors and my colleagues, I want to express our gratitude to Dr. Orfanos and Ms. Lennon for their dedication and valuable contribution to Neurochem. We wish them every success in the future," said Dr. Francesco Bellini, Neurochem's Chairman, President and CEO.
About Neurochem
Neurochem Inc. is a global health company focused on the research, development and commercialization of products to provide innovative health solutions to address critical unmet medical needs.
To Contact Neurochem
For additional information on Neurochem and its drug development programs, please call the North American toll-free number 1-877-680-4500 or visit our Web Site at www.neurochem.com.
Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond Neurochem Inc.'s control. Such risks include but are not limited to: the impact of general economic conditions, general conditions in the pharmaceutical and/or nutraceutical industry, changes in the regulatory environment in the jurisdictions in which the Neurochem group does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation, that actual results may vary once the final and quality-controlled verification of data and analyses has been completed, as well as other risks disclosed in public filings of Neurochem Inc. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. The reader should not place undue reliance, if any, on any forward-looking statements included in this news release. These statements speak only as of the date made and Neurochem Inc. is under no obligation and disavows any intention to update or revise such statements as a result of any event, circumstances or otherwise, unless required by applicable legislation or regulation. Please see the Annual Information Form of Neurochem Inc. for further risk factors that might affect the Neurochem group and its business.
Lise Hebert, PhD, Vice President, Corporate Communications, (450) 680-4572, [email protected]
SOURCE NEUROCHEM INC.
